Citadel Advisors
BCTX

Citadel Advisors’s Briacell Therapeutics BCTX Stock Holding History

Citadel Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-922
Closed -$78.1K – 14467
2024
Q4 		$78.1K Buy
922
+460
+100% +$55.1K ﹤0.01% 11816
2024
Q3 		$85.9K Buy
462
+457
+9,140% +$51.3K ﹤0.01% 11319
2024
Q2 		$912 Sell
5
-153
-97% -$43.3K ﹤0.01% 13893
2024
Q1 		$67.8K Buy
158
+32
+25% +$17.6K ﹤0.01% 11858
2023
Q4 		$111K Buy
+126
New +$90.4K ﹤0.01% 10807
2023
Q3 		– Sell
-50
Closed -$48.1K – 14287
2023
Q2 		$48.1K Buy
+50
New +$49.4K ﹤0.01% 11842
2022
Q4 		– Sell
-1,351
Closed -$1.14M – 14868
2022
Q3 		$1.14M Sell
1,351
-610
-31% -$612K ﹤0.01% 6710
2022
Q2 		$1.7M Sell
1,961
-1,958
-50% -$1.93M ﹤0.01% 5878
2022
Q1 		$5.96M Buy
3,919
+801
+26% +$948K ﹤0.01% 3841
2021
Q4 		$3.87M Buy
+3,118
New +$4.09M ﹤0.01% 4817

Other funds holding BCTX

FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's BCTX Position: Q4 2025 in Review

Citadel Advisors sold out of Briacell Therapeutics (BCTX) in Q4 2025, closing a stake of 11,055 shares — an estimated $122K sold.

Citadel Advisors first reported a position in BCTX in Q2 2023 and held it in 5 quarters. The position peaked at $409K in Q2 2023. 13 funds tracked by Wall St. Rank hold BCTX as of Q4 2025.

  • Citadel Advisors reported no remaining Briacell Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 11,055 Briacell Therapeutics shares in Q4 2025, an estimated $122K.
  • Citadel Advisors first reported a position in Briacell Therapeutics in Q2 2023 and held it in 5 quarters.
  • Citadel Advisors's Briacell Therapeutics position peaked at $409K in Q2 2023.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.